This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Creates Novel Antibody-Cytokine Conjugates For Cancer Therapy

-- Preclinical Study Presented at 2013 Annual Meeting of the American Association for Cancer Research (AACR) --

-- Study on Mechanism of Cancer Metastasis also Reported --

WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) --  Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the creation of a new class of antibody-cytokine conjugates using the Company's patented DOCK-AND-LOCK™ (DNL™) platform technology. These DNL™ complexes demonstrated potent anti-tumor activity in preclinical studies.

The Company has previously reported the development of antibody-directed interferon-alpha 2b (IFN alpha 2b) complexes. (For more information, please refer to the Company's press release at ). Veltuzumab-IFN alpha 2b is the most advanced product from this group of IFN alpha-based DNL™ complexes, and is currently being developed for improved therapy of B-cell malignancies, partially supported by a grant from the Small Business Innovation Research program of the National Cancer Institute totaling $2.8 million.

While functioning similarly to IFN-alpha in eliciting anti-viral, anti-tumor, and immune-modulating activities, IFN-lambda is being considered as a potential alternative to existing IFN-alpha therapeutic regimens due to its more restricted cellular targets. Antibody-targeted IFN- lambda may further improve its safety, potency and pharmacokinetics.

In the current study, 3 DNL TM complexes of IFN- lambda, designated (E1)- lambda 1, (15)- lambda 1, and (C2)- lambda 1, were generated by site-specifically conjugating IFN- lambda 1 to 3 of the Company's proprietary humanized antibodies, hRS7 (anti-TROP-2), hMN-15 (anti-CEACAM6), and hL243 (anti-HLA-DR), respectively. These antibody-cytokine conjugates were evaluated in human malignant cell lines of cervix, colon, esophagus, lung, liver, and skin.

Targeting of these antibody-cytokine conjugates to antigen-expressing cells markedly increased the amount of IFN- lambda 1 localized at the cell surface. As a result, (E1)- lambda 1 inhibited the in vitro proliferation of the cervical, lung and esophageal cancer cell lines at less than 1 picomolar (pM) concentration, which was 1,000-fold more potent than commercial IFN- lambda 1. Likewise, the anti-proliferation activity of (15)- lambda 1 was enhanced ~100-fold in cervical and esophageal cancer cells, but not in CEACAM6-negative lung cancer cells.

"These promising results, attributable to increased localization and stronger binding to antibody-targeted cells, warrant further exploration as potential cancer therapeutics," remarked Cynthia L. Sullivan, President and Chief Executive Officer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.66 -0.09%
FB $118.57 0.84%
GOOG $698.30 0.76%
TSLA $241.82 0.44%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs